RLS-1496 / Rubedo Life Sci - LARVOL DELTA

Clinical study of RLS-1496 topical cream: targeting senescence and oxidative stress via GPX4 inhibition in patients with actinic keratosis (EADV 2026) - No abstract available

Clinical • Late-breaking abstract • Oxidative stress • Actinic Keratosis • Dermatology • GPX4

Evaluate RLS-1496 Topical Cream for Actinic Keratosis (clinicaltrials.gov) - P1/2 | N=24 | Active, not recruiting | Sponsor: Rubedo Life Sciences, Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: May 2026 ➔ Aug 2026

Enrollment closed • Trial completion date • Actinic Keratosis • Dermatology

Clinical study of RLS-1496 topical cream: Targeting cellular senescence in patients with mild-to-moderate plaque psoriasis (SID 2026) - "In conclusion, RLS-1496 cream achieved TE in psoriatic skin at safe clinical doses. Further clinical investigation of RLS-1496 cream in PsO is warranted."

Clinical • Dermatology • Immunology • Plaque Psoriasis • Psoriasis • GPX4 • IL6 • TNFA

Rubedo Life Sciences Announces Positive Preliminary Phase 1 Clinical Trial Results for Lead Drug Candidate RLS-1496 in Patients with Plaque Psoriasis, Atopic Dermatitis, and Skin Aging (Businesswire) - "In psoriasis patients: Clear dose-response seen during the trial (0.1%, 0.5%, and 1.0%); all doses were well-tolerated so only 1.0% dose will be evaluated moving forward; Dose-related target engagement of RLS-1496 and GPX4; Overall reduction in senescent cells seen with RLS-1496 in the mid- and high-dose cohorts...In atopic dermatitis patients: Even higher levels of target engagement and substantial clinical improvement were seen in atopic dermatitis subjects on RLS-1496...Early photo-aging data show: Dose-dependent target engagement in non-lesional photo-aged skin...Additional results from this trial will be presented during an oral presentation at the Society for Investigative Dermatology (SID) from May 13-16, 2026, in Chicago."

P1 data • Atopic Dermatitis • Plaque Psoriasis • Psoriasis

RLS-1496-101: Phase 1 study with topical cream RLS-1496 in patients with plaque psoriasis or Eczema (clinicaltrialsregister.eu) - P1 | N=44 | Completed | Sponsor: Rubedo Life Sciences Italy S.R.L. | Recruiting ➔ Completed

Trial completion • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Evaluate RLS-1496 Topical Cream for Actinic Keratosis (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Rubedo Life Sciences, Inc.

New P1/2 trial • Actinic Keratosis • Dermatology

Clinical Study of RLS-1496 Topical Cream: Targeting Cellular Senescence in Patients with Mild to Moderate Plaque Psoriasis, Atopic Dermatitis, and Aged Skin (ISDS 2025) - "The proportion of patients achieving ≥1-point improvement in mIGA and mean change in WI-NRS pruritus scores. Biomarker changes in skin and blood, senescence-related markers, epigenetic clock, and DLQI will also be evaluated."

Clinical • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Pruritus • Psoriasis

Rubedo Life Sciences Announces U.S. FDA Clearance of IND for Selective GPX4 Modulating Lead Drug Candidate RLS-1496 for Actinic Keratosis, Expands Clinical Advisory Board (Businesswire) - "The study is expected to begin in Q4 2025. "

IND • Actinic Keratosis

The first EMA-cleared RLS-1496 clinical trial began in May 2025 for plaque psoriasis, atopic dermatitis, and skin aging (photoaged skin) (Businesswire) - "Study results are expected in Q4 2025."

P1 data • Trial status • Atopic Dermatitis • Psoriasis

Rubedo Life Sciences Announces First Patient Dosed with Lead Drug Candidate RLS-1496, the First GPX4 Modulator Targeting Pathologic Senescent Cells To Enter Phase 1 Clinical Trial (Businesswire) - "Rubedo Life Sciences, Inc....today announced that the first patient has been dosed with lead drug candidate RLS-1496 in the company’s single-center, ascending-dose, randomized, double-blind, vehicle-controlled trial. The study marks the first time a GPX4 (glutathione peroxidase) modulator has entered Phase 1 clinical trial and is designed to assess the safety, tolerability, clinical effects, plasma bioavailability, and pharmacodynamics of topical RLS-1496 in male or female patients 18 years or older with mild to moderate and stable plaque psoriasis....A systemic formulation of RLS-1496 is planned to enter Phase 1 clinical trials in 2026."

New P1 trial • Trial status • Immunology • Psoriasis

Rubedo Life Sciences Announces Clinical Development Plans for Lead Candidate RLS-1496, a First-in-Class GPX4 Modulator Targeting Aging Cells and Surrounding Tissues (Businesswire) - "Rubedo Life Sciences...announced its clinical development plans for its lead candidate RLS-1496 at the 12th Annual Dermatology Summit....Rubedo’s Chief Scientific Officer Marco Quarta, PhD, also presented details regarding the Phase 1 clinical trial for RLS-1496, which will begin in Spring 2025 in the Netherlands, and the kickoff of the company’s Series B financing round."

Clinical • New P1 trial • Dermatology

A novel mouse model for chronic skin fibrosis induced by Mitomycin C (EADV 2024) - "Introduction & Objectives: Over 50% of all cancer patients receive radiation therapy and/or DNA-damaging drugs known to cause skin damage, including dermatitis, ulceration and in some cases chronic skin fibrosis. This work provides a robust and convenient inflammatory and fibrotic skin model with cellular senescence characteristics, and provides a large time window to test novel therapeutics."

Preclinical • Dermatitis • Dermatology • Fibrosis • Immunology • Oncology • Scleroderma • Systemic Sclerosis

Rubedo Life Sciences Closes $40M Series A Financing Led by Khosla Ventures and Ahren Innovation Capital (Businesswire) - "Rubedo Life Sciences...announced the closing of a $40M Series A financing round. The round was led by Khosla Ventures and Ahren Innovation Capital, with participation from Hevolution, R42, Modi Ventures, Cerigo Investments, Shanda Group, Refactor Capital, LongeVC, Italian Angels for Growth (IAG), and other investors. The funding will be used to advance the company’s lead candidate RLS-1496 in chronic atopic dermatitis and chronic psoriasis, which will be entering Phase 1 studies. Rubedo is also developing additional therapies that selectively target senescent cells in pulmonary diseases with significant unmet medical need, such as idiopathic pulmonary fibrosis (IPF), with a program recipient of a substantial CIRM grant last year."

Financing • Atopic Dermatitis • Idiopathic Pulmonary Fibrosis • Immunology • Psoriasis • Systemic Sclerosis